The Austrian fulvestrant registry: results from a prospective observation of fulvestrant in postmenopausal patients with metastatic breast cancer
- 275 Downloads
Background Endocrine therapy is the preferred treatment in oestrogen- and/or progesterone-receptor (ER/PgR) positive breast cancer. Fulvestrant is a pure ER-antagonist. We present results from the Austrian Fulvestrant Registry. Methods Three-hundred and fifty patients were included. Time to progression (TTP) was defined as primary endpoint. A multivariate analysis was performed to identify factors significantly associated with TTP. Results Fulvestrant was administered as first-line therapy in 26%, second-line in 49%, and third-line or beyond in 25%. TTP was median 7 months. We observed a response in 15% of patients and 41% had SD ≥ 6 months. First-line treatment and non-visceral metastases were associated with longer TTP. One case of pulmonary embolism was reported. Grade 3 toxicities consisted of joint pain (1.4%), nausea (1.4%) and hot flashes (0.3%). Conclusions Fulvestrant was effective and well tolerated. TTP was superior to other trials, due to the large proportion of first-line patients. Activity is apparently independent of Her2-status.
KeywordsEndocrine treatment Fulvestrant Metastatic breast cancer Oestrogen-receptor
Apart from the authors of this manuscript, individuals contributing to the Austrian Fulvestrant Registry included the following: Aiginger P, Andel J, Artner S, Fiegl M, Fortelny A, Gunegger D, Gomar-Hoess C, Halbritter W, Haslbauer F, Hehenwarter W, Hellan J, Hojas S, Horvath W, Kier P, Kis A, Kopetzky G, Kretschmar A, Kührer I, Labuda B, Lass H, Lobmaier G, Loncsar G, Luschin-Ebengreuth G, Magg P, Manfreda D, Medl M, Niedermayer A, Papala T, Paurits T, Rainer G, Reimer D, Renner K, Riedl M, Schenk T, Schmid G, Stangl W, Tichatschek R, Thiel I, Trapl H, Ulsperger E, Urbania A, Walla B, Wette V, Wilthoner K. The Austrian Fulvestrant Registry was supported by a grant from AstraZeneca Pharmaceuticals.
- 4.Paridaens R, Dirix L, Lohrisch C et al (2003) Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. Ann Oncol 14:1391–1398. doi: 10.1093/annonc/mdg362 PubMedCrossRefGoogle Scholar
- 17.Osborne CK, Shou J, Massarweh S et al (2005) Crosstalk between estrogen receptor and growth factor receptor pathways is a cause for endocrine resistance in breast cancer. Clin Cancer Res 11(2 Pt 2):865–870Google Scholar
- 21.Howell A, Robertson JFR, Quaresma Albano J et al (2002) Fulvestrant, formerly ICI 182, 780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 20:3396–3403. doi: 10.1200/JCO.2002.10.057 PubMedCrossRefGoogle Scholar
- 22.Osborne CK, Pippen J, Jones SE et al (2002) Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 20:386–3395. doi: 10.1200/JCO.2002.10.058 CrossRefGoogle Scholar
- 26.Mlineritsch B, Psenak O, Mayer P et al (2007) Fulvestrant („faslodex”) in heavily pretreated postmenopausal patients with advanced breast cancer: single centre clinical experience from the Compassionate Use Programme. Breast Cancer Res Treat 106:105–112. doi: 10.1007/s10549-006-9482-7 PubMedCrossRefGoogle Scholar
- 27.Chia S, Gradisher W, Mauriac L et al (2008) Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromtase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol 26:1664–1670. doi: 10.1200/JCO.2007.13.5822 PubMedCrossRefGoogle Scholar
- 30.Howell A (2002) Postmenopausal women with advanced breast cancer who progress on fulvestrant or tamoxifen retain sensitivity to further endocrine therapies. Breast Cancer Res Treat 76(Suppl 1):72SGoogle Scholar
- 31.Perey L, Paridaens R, Hawle H et al (2007) Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss group for Clinical Cancer Research Trial (SAKK 21/00). Ann Oncol 18:64–69. doi: 10.1093/annonc/mdl341 PubMedCrossRefGoogle Scholar
- 38.Howell A, Robertson JFR, Abram P et al (2004) Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol 22:1605–1613. doi: 10.1200/JCO.2004.02.112 PubMedCrossRefGoogle Scholar